| Literature DB >> 31883413 |
Jonathan Visentin1,2,3, Thomas Bachelet4,5, Olivier Aubert6, Arnaud Del Bello7,8, Charlie Martinez4, Frédéric Jambon2,3,4, Gwendaline Guidicelli1, Mamy Ralazamahaleo1, Charlène Bouthemy1, Marine Cargou1, Nicolas Congy-Jolivet8,9,10, Thoa Nong11, Jar-How Lee11, Rebecca Sberro-Soussan12,13, Lionel Couzi2,3,4, Nassim Kamar7,8,14, Christophe Legendre12,13, Pierre Merville2,3,4, Jean-Luc Taupin1,2,3.
Abstract
Anti-denatured HLA-Cw antibodies are highly prevalent, whereas anti-native HLA-Cw antibodies seem to lead to random flow cytometry crossmatch results. We aimed to reassess crossmatch prediction for anti-HLA-Cw using 2 types of single antigen flow beads (classical beads and beads with diminished expression of denatured HLA), and to compare the pathogenicity of preformed anti-denatured and anti-native HLA-Cw antibodies in kidney transplantation. We performed 135 crossmatches with sera reacting against donor HLA-Cw (classical beads fluorescence ≥500); only 20.6% were positive. Forty-three (31.6%) were anti-denatured HLA antibodies (beads with diminished expression of denatured HLA fluorescence <300); all were crossmatch negative. The correlation between classical beads fluorescence and the crossmatch ratio was low (ρ = 0.178), and slightly higher with beads with diminished expression of denatured HLA (ρ = 0.289). We studied 52 kidney recipients with preformed anti-HLA-Cw donor-specific antibodies. Those with anti-native HLA antibodies experienced more acute and chronic antibody-mediated rejections (P = .006 and .03, respectively), and displayed a lower graft survival (P = .04). Patients with anti-native HLA-Cw antibodies more frequently had previous sensitizing events (P < .000001) or plausibility of their antibody profile according to known anti-native HLA-Cw eplets (P = .0001). Anti-native but not anti-denatured HLA-Cw antibodies are deleterious, which underscores the need for reagents with diminished expression of denatured HLA.Entities:
Keywords: alloantibody; basic (laboratory) research/science; clinical research/practice; crossmatch; flow cytometry; histocompatibility; kidney transplantation/nephrology; major histocompatibility complex (MHC); rejection: antibody-mediated (ABMR)
Mesh:
Substances:
Year: 2020 PMID: 31883413 DOI: 10.1111/ajt.15766
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086